Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jeffrey TL Smith, MD FRCP
Alder Biopharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
43 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rivercity Hospital Research Centre
Auchenflower, Queensland, Australia
- Australian Clinical Research Organisation
Kippa-Ring, Queensland, Australia
- Royal Adelaide Hospital
Adelaide, South Australia, Australia
- Palliative Care Launceston General Hospital
Launceston, Tasmania, Australia
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Atlantic Health Sciences Corporation
Saint John, New Brunswick, Canada
- Mcgill University, Department of Oncology
Montreal, Quebec, Canada
- A. Gvamichava National Cancer Centre
Tbilisi, Georgia
- Medulla Chemotherapy and Immunotherapy Clinic
Tbilisi, Georgia
- Union Cancer Prevention Centre
Tbilisi, Georgia
- Indira Gandhi Institute of Medical Sciences
Patna, Bihar, India
- Dr. Kamakshi Memorial Hospital
Pallikaranai, Chennai, India
- Gknm Hospital
Pappanaickenpalayam, Coimbatore, India
- Curie Manavata Cancer Centre
Nashik, Maharashtra, India
- Kidwai Memorial Institute of Oncology
Bangalore, India
- Kailash Cancer Hospital and Research Centre
Gujarat, India
- Indoamerican Cancer Institute & Research Center
Hyderabad, India
- Searoc Cancer Centre
Jaipur, India
- Orchid Nursing Home
Kolkata, India
- Shatabdi Hospital
Mumbai, India
- Tata Memorial Hospital
Mumbai, India
- Mahavir Cancer Sansthan
Patna, India
- Jehangir Clinical Development Centre Pvt. Ltd.
Pune, India
- P3 Research Ltd
Tauranga, New Zealand
- Oddzial Chorob Pluc I Leczenia Raka Pluc
Bydgoszcz, Poland
- Oddzial Chemioterapii Szpital Morski
Gdynia, Poland
- Ii Oddzia Chorob Pluc Z Pododdzialem Chemioterapii
Krakow, Poland
- Oddzial Ii Chemioterapii Specjalistyczny Szpital
Szczecin, Poland
- Professor Dr. Al Trestioreanu Institute
Bucharest, Romania
- Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy
Cluj-Napoca, Romania
- Oradea Clinical County Hospital Medical Oncology Department
Oradea, Romania
- County Hospital Sibiu Medical Oncology Department
Sibiu, Romania
- Republic Oncology Dispensary
Ufa, Bashkortostan Republic, Russia
- Territorial Clinical Oncology Dispensary
Krasnodar, Krasnodar Territory, Russia
- Stavropol Territorial Clinical
Pyatigorsk, Stavropol Territory, Russia
- City Clinical Hospital No. 1
Novosibirsk, Russia
- Saint-Petersburg State Medical University, I.P. Pavlov
Saint Petersburg, Russia
- St. Petersburg City Oncology Dispensary
Saint Petersburg, Russia
- Yaroslavl Regional Clinical Oncology Hospital
Yaroslavl, Russia
- Clinical Hospital Center Bezanijska Kosa
Belgrade, Serbia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2008
- Primary completion
- 31 Aug 2009
- Completion
- 31 Dec 2009
- Last update posted
- 9 Jul 2020
- Registered enrollment
- 124
- Registry id
- NCT00866970
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.